Rebamipide enemas - New effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis

Digestive Diseases and Sciences

Volumn 50, Issue SUPPL. 1, 2005, Pages

  Miyata, Mitsuki ^a   Kasugai, Kunio ^a   Ishikawa, Tetsuya ^a   Kakumu, Shinichi ^a   Onishi, Masafumi ^a   Mori, Takeshi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Long term administration; Rebamipide enema; Steroid dependency; Steroid resistance; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; ENEMA; REBAMIPIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLONOSCOPY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALANINE; ANTI-ULCER AGENTS; COLITIS, ULCERATIVE; DRUG RESISTANCE; ENEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUINOLONES; SEVERITY OF ILLNESS INDEX;

EID: 25644451201     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2816-1     Document Type: Article

References (25)

1. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625-1629, 1987
2. Sninsky CA, Cort DH, Shanaban F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A Multicenter study [see comments]. Ann Intern Med 115:350-355, 1991
3. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88:1188-1197
4. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S: Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 40:296-304, 1995
5. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF: A trial of zileuton versus mesalamine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group for Ulcerative Colitis. Gastroenterology 112:718-724, 1997
6. Hanauer S, Sninsky C, Robinson M, Powers B, McHattie J, Mayle J: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 124:204-211, 1996
7. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G: Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 13:373-379, 1999
8. Faubion WA Jr, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255-260, 2001
9. Makiyama K, Takeshima F, Kawasaki H: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838-1839, 2000
10. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effect of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43:160S-166S, 1998
11. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radical Biol Med 18:117-123, 1995
12. Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide by electron spin resonance. Arzneim-Forsch/Drug Res 43:363-366, 1993
13. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y: Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608-1616, 2000
14. Farup PG, Hinterleitner TA, Lukas M, Hebuterne X, Rachmilewitz D, Campieri M, Meier R, Keller R, Rathbone B, Oddsson E: Mesalamine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 7:237-242, 2001
15. Rachmilewitz D on behalf of an international study group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 298:82-86, 1989
16. Floren CH, Benoni C, Willen R: Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 22:459-162, 1987
17. Sood A, Midha V, Sood N, Avasthi G: Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 22:79-81, 2003
18. Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, Izawa H, Yamamura M, Amano K, Satomi M, Shimoyama T: Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apher 1:207-211, 1997
19. Rayner CK, McCormack G, Emmanuel AV, Kamm MA: Long-term results of low-dose intravenous cyclosporine for acute severe ulcerative colitis. Aliment Pharmacol Ther 18:303-308, 2003
20. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 8:231-233, 2004
21. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford R: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis. N Engl J Med 349:350-357, 2003
22. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43:90S-98S, 1998
23. Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F: Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter fells. Scand J Gastroenterol 35:470-175, 2000
24. Matysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M: Alteration of epithelial permeability by Helicobacter and IL-1β in vitro: protective effect of rebamipide. Dig Dis Sci 46:1558-1566, 2001
25. Tarnawski A, Chai J, Pai R, Chiou SK: Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49:202-209, 2004